Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may predict who benefits from back pain nerve block

NCT ID NCT07776379

Knowledge-focused Sponsor: Keimyung University Dongsan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study explores whether the level of a protein called BDNF in the blood can predict how well patients with chronic low back pain respond to a treatment called an erector spinae plane block, a nerve block that aims to relieve pain. Researchers will measure BDNF levels in 70 adults with chronic low back pain due to disc degeneration or spinal stenosis, then perform the block and track whether it provides pain relief. The goal is to see if BDNF could serve as a simple biomarker to guide treatment decisions for this common and debilitating condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Erector spinae plane block using ropivacaine, along with blood sampling to measure BDNF levels
What this could lead to
If successful, this could help doctors predict which patients with chronic low back pain will benefit from a specific nerve block, leading to more personalized pain management.
What could go wrong
This is a small, early-stage study. The relationship between BDNF and pain is complex and may not reliably predict outcomes. The procedure itself carries typical risks like infection or nerve damage, though rare.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

low back pain population with disc degeneration confirmed in MRI

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic low back pain patients with or without leg pain due to disc degeneration or spinal stenosis * Patients who have MRI Exclusion Criteria: * Secondary low back pain (spine fracture, infection, tumor) * recent history of spine surgery * systemic inflammatory disease (rheumatoid arthritis, SLE, ankylosing spondylitis) * peripheral neuropathy or central nervous system injury * fibromyalgia * drugs which can affect the serum BDNF level (anti depressant, anti parkinsonian drug, acetylcholinesterase inhibitor, anti psychotics)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain derived neurotrophic factor level are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain derived neurotrophic factor level Chronic low back pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ji Hee

    RECRUITING

    Daegu, Daegu, 42601, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.